Description
PRIME PRIMOBOLAN 200 – Metenolone Enanthate 200mg/ml
PRIME PRIMOBOLAN 200 offers a concentrated formulation of Metenolone Enanthate, specifically engineered for advanced users seeking an anabolic agent with an exceptional safety profile and minimal estrogenic and androgenic activity. Recognized for its tissue-selective properties, it is often used during refinement or therapeutic phases.
Mechanism of Action:
Metenolone promotes nitrogen retention and lean muscle preservation with almost no conversion to estrogen. Its enanthate ester allows for prolonged and stable plasma levels, which enhances metabolic support during cutting cycles or periods of physical recovery.
Use Case:
Recommended for users aiming to maintain muscle mass while in a caloric deficit or preparing for physique refinement. Frequently used in therapeutic bridging or in stacks requiring minimal systemic disruption or hormonal fluctuation.
Advantages of High-Concentration Format:
At 200mg/ml, this formulation allows for reduced injection frequency while maintaining optimal serum levels, offering convenience and dosing precision in long-term protocols.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.